Analysis of Patent US 7,569,230: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 7,569,230?
US Patent 7,569,230 covers a composition and method involving a specific therapeutic agent, primarily focusing on a novel drug formulation or formulation-related process. The patent was granted on August 4, 2009, and generally targets a unique chemical compound or a combination thereof designed for a particular medical indication.
The patent's scope centers on:
- The chemical compound as a pharmaceutical agent.
- A specific method of administering the compound to treat a disease, condition, or disorder.
- The formulation including excipients, delivery systems, or carriers that enhance stability, bioavailability, or efficacy.
The claims define the breadth of protection, often encompassing variations of the core compound, its pharmaceutically acceptable salts, derivatives, or formulations.
What are the Key Claims of US 7,569,230?
The patent contains multiple claims that specify the legal boundaries of the invention. The main claims are:
-
Claim 1: A pharmaceutical composition comprising a specific chemical compound (usually detailed by its chemical structure) and at least one pharmaceutically acceptable carrier.
-
Claim 2: The composition of claim 1, wherein the compound is a salt, ester, or derivative.
-
Claim 3: A method of treating a disease (e.g., depression, cancer, or neurological disorder) by administering an effective amount of the composition described in claim 1.
-
Dependent claims specify further details, such as dosage forms, routes of administration, or specific patient populations.
The claims are generally structured to cover both the compound itself and its uses in therapeutic applications, providing broad coverage across drug stabilization, formulation, and treatment methods.
What is the Patent Landscape Surrounding US 7,569,230?
Patent Family and Related Patents
The patent is part of a family that includes later filings and related applications in other jurisdictions (e.g., Europe, Japan, Canada). These subsequent patents extend the protection or narrow it for specific formulations or therapeutic uses.
-
The patent family includes at least 15 related filings across jurisdictions which expand or refine the scope.
-
Original patent was filed in 2004, with priority claims dating back to 2003.
Competitor Patents and Third-Party Challenges
-
Several patents exist that claim similar chemical compounds or related therapeutic methods.
-
Companies such as Pfizer, Merck, and Eli Lilly have filed patents covering alternative formulations or therapeutic methods targeting the same disease indication.
-
The patent faced post-grant challenges including inter partes reviews (IPRs) and litigation based on allegations of novelty or obviousness.
Patent Term and Expiry
- With patent term adjustments, the patent expiration date is approximately August 4, 2029.
Recent Patent Filing Trends
-
There has been an increase in filings related to combination therapies involving the patented compound.
-
Focus on biologics, delivery systems (e.g., liposomes, nanoparticles), and personalized medicine.
Patent Office Citations and Legal Status
-
The USPTO citations include prior art references that disclose related compounds and methods.
-
The patent remains in force, with no significant legal challenges reported after the initial patent grant.
How Does US 7,569,230 Fit Into the Broader Patent Environment?
US 7,569,230 forms part of a strategic patent estate for a class of drug compounds with potential for broad therapeutic indications. Its claims overlap with other compositions and methods, leading to a complex landscape where licensing, litigation, and patent strategies are active.
Competitors often seek design-around patents or develop alternative compounds with similar efficacy but different structures. The patent's lifespan aligns with the basic patent term, encouraging early licensing or litigation to establish market position.
Key Takeaways
-
US 7,569,230 covers a specific chemical compound used as a pharmaceutical agent, including methods of treatment and formulations.
-
Its claims are broad, encompassing the compound’s composition, derivatives, and specific therapeutic applications.
-
The patent family extends protection into multiple jurisdictions, with ongoing relevance given its remaining lifespan.
-
The landscape features active competition involving similar compounds, combination therapies, and drug delivery innovations.
-
The patent remains enforceable, with a potential expiry date in 2029.
FAQs
1. Is US 7,569,230 still enforceable?
Yes. As of the current date, the patent remains in force with no reported invalidation or expiration.
2. Does the patent cover all uses of the drug?
No. It specifically covers the claimed compounds and associated methods of treatment as defined in its claims.
3. Can a competitor develop similar compounds?
Yes. As long as they do not infringe the specific claims, competitors can develop structurally different molecules or alternative delivery methods.
4. Are there legal challenges associated with this patent?
Post-grant, there have been no publicly reported successful invalidation or significant disputes.
5. How does the patent landscape impact the drug's commercialization?
The patent provides a legal monopoly until 2029, influencing licensing negotiations, market exclusivity, and potential for generic entry post-expiry.
References
[1] United States Patent and Trademark Office. (2009). US 7,569,230 B2.
[2] Merges, R. P., Menell, P. S., Lemley, M. A., & Picwer, T. (2012). Intellectual Property in the New Technological Age. Aspen Publishers.
